Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling

• DOI: 10.1186/s12933-022-01614-5
• Publication Date: 2022-09-28T11:03:58Z
• Authors: Jinchun Wu; Tao Liu; Shaobo Shi; Zhixing Fan; Roddy Hiram; Feng Xiong; Bo Cui; Xiaoling Su; Rong Chang; Wei Zhang; Min Yan; Yanhong Tang; He Huang; Gang Wu; Congxin Huang
• Keywords: Heart Failure; Pulmonary Arterial Hypertension; Monocrotaline; Ventricular Remodeling; Research; Ventricular Dysfunction, Right; Sodium; Arrhythmias, Cardiac; Dapagliflozin; Pulmonary arterial hypertension; Rats; 3. Good health; Disease Models, Animal; Ventricular arrhythmias; Glucose; Glucosides; RC666-701; Connexin 43; Diseases of the circulatory (Cardiovascular) system; Animals; Calcium; Calcium handling; Right heart failure; Benzhydryl Compounds; Fura-2

Abstract Background Malignant ventricular arrhythmia (VA) is a major contributor to sudden cardiac death (SCD) in patients with pulmonary arterial hypertension (PAH)-induced right heart failure (RHF). Recently, dapagliflozin (DAPA), a sodium/glucose cotransporter-2 inhibitor (SGLT2i), has been found to exhibit cardioprotective effects in patients with left ventricular systolic dysfunction. In this study, we examined the effects of DAPA on VA vulnerability in a rat model of PAH-induced RHF.

Methods Rats randomly received monocrotaline (MCT, 60 mg/kg) or vehicle via a single intraperitoneal injection. A day later, MCT-injected rats were randomly treated with placebo, low-dose DAPA (1 mg/kg/day), or high-dose (3 mg/kg/day) DAPA orally for 35 days. Echocardiographic analysis, haemodynamic experiments, and histological assessments were subsequently performed to confirm the presence of PAH-induced RHF. Right ventricle (RV) expression of calcium (Ca2+) handling proteins were detected via Western blotting. RV expression of connexin 43 (Cx43) was determined via immunohistochemical staining. An optical mapping study was performed to assess the electrophysiological characteristics in isolated hearts. Cellular Ca2+ imaging from RV cardiomyocytes (RVCMs) was recorded using Fura-2 AM or Fluo-4 AM.

Results High-dose DAPA treatment attenuated RV structural remodelling, improved RV function, alleviated Cx43 remodelling, increased the conduction velocity, restored the expression of key Ca2+ handling proteins, increased the threshold for Ca2+ and action potential duration (APD) alternans, decreased susceptibility to spatially discordant APD alternans and spontaneous Ca2+ events, promoted cellular Ca2+ handling, and reduced VA vulnerability in PAH-induced RHF rats. Low-dose DAPA treatment also showed antiarrhythmic effects in hearts with PAH-induced RHF, although with a lower level of efficacy.

Conclusion DAPA administration reduced VA vulnerability in rats with PAH-induced RHF by improving RVCM Ca2+ handling.